|
Variable category
|
Total (175, 100%)
|
Reinfected group (26, 14.9%)
|
Continuously eradicated group (149, 85.1%)
|
p-value*
|
|---|
|
Gender
|
(N = 175)
|
(n = 26)
|
(n = 149)
| |
|
Male
|
(104, 59.4%)
|
(16, 61.5%)
|
(88, 59.1%)
|
0.75
|
|
Female
|
(71, 40.6%)
|
(10, 38.5%)
|
(61, 40.9%)
| |
|
Age (years) (mean ± SD)
|
(N = 175)
|
(n = 26)
|
(n = 149)
| |
|
(56.6 ± 9.4)
|
(57.6 ± 9.4)
|
(56.4 ± 9.5)
|
|
20-29
|
(2, 1.1%)
|
(0, 0.0%)
|
(2, 1.3%)
|
0.47
|
|
30-39
|
(4, 2.3%)
|
(0, 0.0%)
|
(4, 2.7%)
| |
|
40-49
|
(34, 19.4%)
|
(8, 30.8%)
|
(26, 17.4%)
| |
|
50-59
|
(61, 34.9%)
|
(6, 23.1%)
|
(55, 36.9%)
| |
|
60-69
|
(62, 35.4%)
|
(9, 34.6%)
|
(53, 35.6%)
| |
|
70-79
|
(11, 6.3%)
|
(3, 11.5%)
|
(8, 5.4%)
| |
|
80-89
|
(1, 0.6%)
|
(0, 0.0%)
|
(1, 0.7%)
| |
|
Clinical diagnosis
|
(N = 175)
|
(n = 26)
|
(n = 149)
| |
|
Early gastric cancer
|
(40, 22.9%)
|
(7, 26.9%)
|
(33, 22.1%)
|
0.74
|
|
Dysplasia
|
(19, 10.9%)
|
(4, 15.4%)
|
(15, 10.1%)
| |
|
Peptic ulcer disease
|
(34, 19.4%)
|
(7, 26.9%)
|
(27, 18.1%)
| |
|
Chronic gastritis
|
(82, 46.9%)
|
(8, 30.8%)
|
(74, 49.7%)
| |
|
Histological AG in either antrum or body
|
(N = 116)
|
(n = 20)
|
(n = 96)
| |
|
Yes
|
(67, 57.8%)
|
(14, 70.0%)
|
(53, 55.2%)
|
0.14
|
|
No
|
(49, 42.2%)
|
(6, 30.0%)
|
(43, 44.8%)
| |
|
Histological IM in either antrum or body
|
(N = 144)
|
(n = 21)
|
(n = 123)
| |
|
Yes
|
(84, 58.3%)
|
(10, 47.6%)
|
(74, 60.2%)
|
0.20
|
|
No
|
(60, 41.7%)
|
(11, 52.4%)
|
(49, 39.8%)
| |
|
Regimen
|
(N = 175)
|
(n = 26)
|
(n = 149)
| |
|
EBMT
|
(59, 33.7%)
|
(7, 26.9%)
|
(52, 34.9%)
|
0.23
|
|
MEA
|
(116, 66.3%)
|
(19, 73.1%)
|
(97, 65.1%)
| |
-
EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis; IM, intestinal metaplasia.
- All of early gastric cancer patients were cured by endoscopic submucosal dissection.
-
* P-value for Log-rank test.
